Solicitudes publicadas en los últimos 30 días / Applications published in the last 30 days
NºPublicación: WO2017011826A1 19/01/2017
UNIV CASE WESTERN RESERVE [US]
Anti-lymphoma plant virus particles are described. The anti-lymphoma plant virus particles include a filamentous or rod-shaped plant virus particle linked to an antimitotic agent. A therapeutically effective amount of an anti-lymphoma plant virus particle can be administered to a subject to provide a method of treating lymphoma.
NºPublicación: WO2017010448A1 19/01/2017
NAT UNIV CORP KUMAMOTO UNIV [JP]
The purpose of the present invention is to provide a method for the expansion culture of nephron progenitor cells while maintaining an undifferentiated state. Another purpose of the present invention is to provide an expansion culture method for cultured nephron progenitor cells to have nephron-forming ability. Yet another purpose of the present invention is to provide an expansion culture method for nephron progenitor cells that makes it possible to achieve an excellent expansion rate. The present invention provides a method for culturing and increasing nephron progenitor cells created from isolated mammalian nephron progenitor cells or iPS cells using a medium containing the following compounds: (i) Wnt agonist; (ii) Notch inhibitor; (iii) Bmp; (iv) leukemia inhibitory factor; (v) Rock inhibitor; and (vi) Fgf.
NºPublicación: WO2017011314A1 19/01/2017
PAHARMACYCLICS LLC [US]
Methods of treating a lymphoma comprising co-administering to an individual in need thereof a Btk inhibitor and an HDAC inhibitor compound are provided.
NºPublicación: WO2017011323A1 19/01/2017
UNIV MARYLAND [US]
Compounds that inhibit Myeloid Cell Leukemia-1 (Mcl-1) oncoprotein, and methods of using the same, are provided for treating disease.
NºPublicación: EP3117009A1 18/01/2017
INST NAT DE LA SANT\u00C9 ET DE LA RECH M\u00C9DICALE (INSERM) [FR]
UNIV DE ROUEN [FR]
CENTRE HENRI BECQUEREL [FR]
The present invention relates to a method for classifying a diffuse large B-cell lymphoma (DLBCL) of a subject into a GCB-DLBCL or into a ABC-DLBCL comprising the step of determining the expression level of 10 genes in a tumor tissue sample obtained from the subject by performing a Reverse Transcriptase Multiplex Ligation dependent Probe Amplification (RT-MLPA) assay wherein the 10 genes are NEK6, IRF4, IGHM, LMO2, FOXP1, TNFRSF9, BCL6, TNFRSF13B, CCND2 and MYBL1.
NºPublicación: EP3118220A1 18/01/2017
OXFORD BIOTHERAPEUTICS LTD [GB]
The present invention provides methods and compositions for screening, diagnosis and prognosis of colorectal cancer, kidney cancer, liver cancer, lung cancer, lymphoid leukaemia (particularly chronic lymphocytic leukaemia), ovarian cancer or pancreatic cancer, for monitoring the effectiveness of colorectal cancer, kidney cancer, liver cancer, lung cancer, lymphoid leukaemia (particularly chronic lymphocytic leukaemia), ovarian cancer or pancreatic cancer treatment, and for drug development.
NºPublicación: EP3118221A1 18/01/2017
OXFORD BIOTHERAPEUTICS LTD [GB]
The present invention relates to the identification of membrane proteins associated with B-cell non-Hodgkin's lymphoma, breast cancer, cervical cancer, colorectal cancer, gastric cancer, glioblastoma, hepatocellular carcinoma, lung cancer, lymphoid leukaemia (particularly acute T- cell leukaemia and chronic lymphocytic leukaemia), melanoma, neuroblastoma, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, renal cell cancer and retinoblastoma which have utility as markers and for treatment of said cancers and which also form biological targets against which antibodies such as therapeutic antibodies (or other affinity reagents) or other pharmaceutical agents can be made.
NºPublicación: US2017007561A1 12/01/2017
HAUSHEER FREDERICK H [US]
BIONUMERIK PHARMACEUTICALS INC
The present invention discloses and claims novel pharmaceutical compositions, methods, and kits used for the contemporaneous, heterogeneously-oriented, multi-targeted therapeutic modification and/or modulation of cellular metabolic anomalies or other undesirable physiological conditions, including cancer, where the normal cellular biochemical function and/or the expression levels of various proteins/enzymes (i.e., the target molecules) are abnormal and must be modified and/or modulated in order to treat these metabolic anomalies or other undesirable physiological conditions, including cancer. The aforementioned target molecules, by way of non-limiting example, include: anaplastic lymphoma kinase (ALK), mesenchymal epithelial transition (MET) kinase, the receptor tyrosine kinase (ROS1), epidermal growth factor receptor (EGFR), peroxiredoxin (Prx), excision repair cross-complementing protein 1 (ERCC1), insulin growth factor 1 receptor (IGF1R), ribonucleotide reductase (RNR), tubulin, farnesyltransferase, and various other classes of proteins/enzymes. Additionally, the present invention discloses and claims methods and kits for (a) the selection of subjects for treatment; (b) the determination of the most effective medicinal agent(s) to be administered in combination with the administration of the sulfur-containing, amino acid-specific small molecules of the present invention; (c) the dosage of the medicinal agent(s) to be administered; (d) the determination of the length and/or
NºPublicación: US2017007590A1 12/01/2017
CELGENE CORP [US]
Compounds of formula I for treating, preventing or managing cancer are disclosed. Also disclosed are methods of treating, preventing or managing cancer, such as leukemia, comprising administering the compounds. In certain embodiments, the method of treatment comprise administering a compound provided herein in combination with a second agent. Pharmaceutical compositions and single unit dosage forms comprising the compounds are also disclosed.
NºPublicación: US2017008976A1 12/01/2017
UNIV MONASH [AU]
MEMORIAL SLOAN-KETTERING CANCER CENTRE [US]
LUDWIG INST FOR CANCER RES LTD [US]
Expression of proteolytically active, high molecular weight ADAM protease is relatively increased in tumour cells that also express the putative tumour stem cell marker CD133. An antibody or antibody fragment such as 8C7 monoclonal antibody may be used to selectively bind to proteolytically active, high molecular weight ADAM10 protease to thereby detect tumour cells and also as a therapeutic agent for treating cancers, tumours and other malignancies inclusive of leukemia, lymphoma, lung cancer, colon cancer, adenoma, neuroblastoma, brain tumour, renal tumour, prostate cancer, sarcoma and/or melanoma.
NºPublicación: US2017007685A1 12/01/2017
THE BOARD OF REGENTS OF THE UNIV OF TEXAS SYSTEM [US]
UNIV YALE [US]
THE US SECRETARY [US]
THE UNITED STATES OF AMERICA AS REPRESENTED BY TH E SECRETARY DEPT OF HEALTH AND HUMAN SERVI [US]
A lymphoma cell line was engineered to express surface IgG1 Fc. These tumor cells were taken up rapidly by DCs, leading to enhanced cross-presentation of tumor-derived antigen to CD8 T cells. IgG1-Fc tumors failed to grow in vivo and prophylactic vaccination in an animal model resulted in rejection of unmanipulated tumor cells. Furthermore, IgG1-Fc tumor cells were able to slow the growth of an unmanipulated primary tumor when used as a therapeutic tumor vaccine. This demonstrates that engagement of Fc receptors by tumors expressing the Fc region of IgG1 can induce efficient and protective anti-tumor CD8+ T cell responses without prior knowledge of tumor-specific antigen.
NºPublicación: AU2015274408A1 12/01/2017
This document provides methods and materials related to treating lymphomas. For example, methods and materials relating to the use of a composition containing albumin-containing nanoparticle/antibody complexes (e.g., ABRAXANE®/anti-CD20 polypeptide antibody complexes) to treat lymphomas are provided.
NºPublicación: AU2015277494A1 12/01/2017
This document provides methods and materials related to treating myelomas. For example, methods and materials relating to the use of a composition containing albumin-containing nanoparticle/antibody complexes (e.g., ABRAXANE®/anti-CD38 polypeptide antibody complexes) to treat myelomas are provided.
NºPublicación: US2017007605A1 12/01/2017
GATHMANN INSA [CH]
MAHON FRANCOIS-XAVIER [FR]
MOLIMARD MATHIEU [FR]
PICARD STEPHANE [FR]
WANG YANFENG [US]
NOVARTIS AG [CH]
The present invention provides a method of treating Philadelphia positive (Ph+) leukemia, such as Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) or chronic myeloid leukemia (CML), in a human patient population comprising the steps of (a) administering a predetermined fixed amount of a Bcr-Abl tyrosine kinase inhibitor, such as Imatinib, or a pharmaceutically acceptable salt thereof to human patients suffering from a Ph+ leukemia, (b) collecting at least one blood sample from said patients, (c) determining the plasma trough level (Cmin) of the Bcr-Abl tyrosine kinase inhibitor or of a metabolite thereof as well as the MMR rates, (d) assessing a discrimination potential of trough plasma concentrations for MMR and identifying a Cmin threshold for optimal sensitivity and specificity and (e) adjusting the dose of the inhibitor of the Bcr-Abl tyrosine kinase or a pharmaceutically acceptable salt thereof applied to the individual patients from said patient population and, optionally, future patients suffering from a Ph+ leukemia in a manner that a Cmin is achieved in each single patient equal to or higher than the Cmin threshold obtained under step (d).
NºPublicación: US2017007611A1 12/01/2017
PHARMACYCLICS LLC [US]
Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
NºPublicación: EP3115049A1 11/01/2017
ABBVIE BIOTHERAPEUTICS INC [US]
DANA-FARBER CANCER INST INC [US]
Composition suitable for treating multiple myeloma in subject, comprising a therapeutically effective amount of HuLuc63, a therapeutically effective amount of lenalidomide and/or bortezomib, and a pharmaceutically acceptable carrier, wherein said composition is capable of being administered in a single or multiple dose regimen.
NºPublicación: EP3114241A1 11/01/2017
HACKENSACK UNIV MEDICAL CENTER [US]
The described invention comprises methods for predicting recurrence of Hodgkin Lymphoma (HL) and poor clinical outcome in a Hodgkin Lymphoma (HL) subject. The methods comprise providing a sample from the HL subject and a sample from a good clinical outcome control subject; isolating total RNA comprising Fibroblast Growth Factor-2 (FGF2) and Syndecan-1 (SDC1) RNA from the sample from the HL subject and from the sample from the good clinical outcome control subject; amplifying the total RNA; measuring a level of expression of the FGF2 and the SDC1 RNA in the HL subject and in the good clinical outcome control subject; and comparing the level of expression of the FGF2 and the SDC1 RNA expressed by the HL subject with the level of expression of the FGF2 and the SDC1 RNA expressed by the good clinical outcome control subject. An increased level of expression of the FGF2 RNA and the SDC1 RNA expressed by the HL subject compared to the level of expression of the FGF2 RNA and the SDC1 RNA expressed by the good clinical outcome control subject is indicative of recurrence of HL or poor clinical outcome for the HL subject. The described invention further comprises a method of detecting evidence of metastatic Hodgkin lymphoma in a Hodgkin Lymphoma (HL) subject by measuring an increased level of expression of CD30, FGF2 and SDC1 RNA in an HL subject compared to a good clinical outcome control subject.
NºPublicación: HK1217303A1 06/01/2017
YIFAN XINFU PHARMACEUTICAL CO LTD [CN]
The invention relates to the field of leukemia medicine, in particular to a medicine composition for treating leukemia and a preparation method thereof. The medicine composition is mainly prepared from, by weight, 2-8% of realgar, 25-42% of indigo naturalis, 50-60% of salviae miltiorrhizae and 6-10% of radix pseudostellariae. The preparation method of salviae miltiorrhizae is improved, the amount of water added to salviae miltiorrhizae is decreased, the number of decoction times is decreased, the decoction time is shortened, it is ensured that effective components of salviae miltiorrhizae are not damaged, the effective component tanshinone IIA for controlling indexes is detected through a high performance liquid chromatograph, the extraction rate reaches 75%, activity of all effective components is well kept, and the extraction rate is kept at a high level. When the medicine composite improved according to the prior art is used for treating leukemia clinically, the complete remission rate reaches 92.9%, the treatment effect is obviously increased and improved, and toxic and side effects are greatly reduced.
NºPublicación: HK1217350A1 06/01/2017
KATHOLIEKE UNIV LEUVEN [BE]
The invention provides methods for treating myelodysplasia syndrome (MDS). The invention is generally directed to reducing certain overt symptoms and disease-causing biological events in MDS by administering certain cells to a subject having MDS. The invention is also directed to drug discovery methods to screen for agents that modulate the ability of the cells to affect these events. The invention is also directed to cell banks that can be used to provide cells for administration to a subject, the banks comprising cells having desired potency for affecting these events.
NºPublicación: US2017000829A1 05/01/2017
SICHUAN GOODDOCTOR PANXI PHARMACEUTICAL CO LTD [CN]
The present invention provides an application of a periplaneta americana medicinal powder or a periplaneta americana extract in preparation for a medicine used for preventing and treating radiation-induced damages. The medicine is capable of preventing and treating the damages caused by radiation therapy for nasopharyngeal cancer, esophageal cancer, stomach cancer, lung cancer, liver cancer, breast cancer, waldeyer's lymphoma, and other cancers. Through test verification, the medicine of the present invention has an obvious prevention and treatment effect for damages caused by radiation therapy for patients with breast tumours and breast cancer after surgery.
NºPublicación: AU2015277230A1 05/01/2017
This application provides improved cell culture media and cell culture methods comprising N-acetylcysteine. These improved cell culture media and cell culture methods increase cell viability, cellular growth rate and/or reduce cell doubling time of cholesterol auxotrophic cells, myeloma cells, and hybridoma cells.
NºPublicación: WO2017003430A1 05/01/2017
SIRBA LTD [CY]
JAGGI MANU [IN]
SINGH ANU [IN]
SHRAIBOM NADAV [CY]
STEINBERG ERAN [US]
A treatment regimen for psoriasis, eczema or other skin ailment, inflammation, autoimmune disease, leukemia, melanoma or other cancer includes administering to a patient a methotrexate regimen along with periodic doses of an herbal combination including Sheng Di Huang, Da Huang or Jin Yin Hua or combinations thereof.
NºPublicación: WO2017001354A1 05/01/2017
ASTRAZENECA AB [SE]
Provided are a series of novel pyridine or pyrimidine derivatives of Formula (I) which inhibit CDK9 and may be useful for the treatment of hyperproliferative diseases. In particular the compounds are of use in the treatment of proliferative diseases such as cancer including hematological malignancies such as acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia, diffuse large B cell lymphoma, Burkitt's lymphoma, follicular lymphoma and solid tumors such as breast cancer, lung cancer, neuroblastoma and colon cancer. A is C(R5) or N; R5 is H, C1-3alkyl, CN or halogen; R2 is optionally substituted 3-7 membered heterocycloalkyl or 3-7 membered cycloalkyl; R4 is (A) or (B) wherein X and Y together with the atoms to which they are attached form an optionally substituted, saturated or partially saturated 5 to 7 membered heterocycloalkyl ring which, in addition to the bridge nitrogen, may contain one or two heteroatoms selected from N, O, and S; J is N or CR11; and R11 is H or C1-3alkyl.
NºPublicación: WO2017001812A1 05/01/2017
IMP INNOVATIONS LTD [GB]
This invention provides compounds of formula (I) and salts thereof, which have activity as inhibitors of N-myristoyl transferase (NMT). The invention also relates to uses of such compounds as medicaments, in particular in the treatment of a disease or disorder in which inhibition of N-myristoyl transferase provides a therapeutic or prophylactic effect, including protozoan infections (such as malaria and leishmaniasis), viral infections (such as human rhinovirus and HIV), and hyperproliferative disorders (such as B-cell lymphoma).
Nº publicación: US2017000837A1 05/01/2017
SIRBAL LTD [CY]
Resumen de: US2017000837A1
A treatment regimen for psoriasis, eczema or other skin ailment, inflammation, autoimmune disease, leukemia, melanoma or other cancer includes administering to a patient a known or discovered treatment regimen along with periodic doses of an herbal combination including Sheng Di Huang, Da Huang or Jin Yin Hua or combinations thereof.